AMENDMENTS TO THE CLAIMS

Please amend the claims to read as follows, and cancel without prejudice or disclaimer to resubmission in a divisional or continuation application claims indicated as cancelled:

1. (Currently amended) A method of treating a subject with hot flashes, said method comprising the step of administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof, wherein said anti-estrogen is Toremifene.

2. -4. Cancelled.

5. (Original) The method according to claim 1, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical composition in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical composition; orally administering to said subject said pharmaceutical composition in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical composition.

6. (Original) The method according to claim 5 wherein said pharmaceutical composition is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.

7. (Currently amended) The method according to claim 1, wherein ~~said antiestrogen~~ Toremifene is administered at a dosage of about 20 mg per day.

8. (Currently amended) The method according to claim 1, wherein ~~said antiestrogen~~ Toremifene is administered at a dosage of about 40 mg per day.

9. (Currently amended) The method according to claim 1, wherein ~~said antiestrogen~~ Toremifene is administered at a dosage of about 60 mg per day.

10. (Currently amended) The method according to claim 1, wherein ~~said antiestrogen~~ Toremifene is administered at a dosage of 80 mg per day.

11. (Withdrawn) A method of suppressing, inhibiting or reducing the risk of hot flashes, said method comprising the step of administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof.

12. (Withdrawn) The method according to claim 11, wherein the anti-estrogen is a selective estrogen receptor modulator (SERM).

13. (Withdrawn) The method according to claim 11, wherein the anti-estrogen is a triphenylethylene.

14. (Withdrawn) The method according to claim 11, wherein the anti-estrogen is Toremifene.

15. (Withdrawn) The method according to claim 11, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical composition in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical composition; orally administering to said subject said pharmaceutical composition in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical composition.

16. (Withdrawn) The method according to claim 15, wherein said pharmaceutical composition is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.

17. (Withdrawn) The method according to claim 11, wherein said antiestrogen is administered at a dosage of about 20 mg per day.

18. (Withdrawn) The method according to claim 11, wherein said antiestrogen is administered at a dosage of about 40 mg per day.

19. (Withdrawn) The method according to claim 11, wherein said antiestrogen is administered at a dosage of about 60 mg per day.

20. (Withdrawn) The method according to claim 11, wherein said antiestrogen is administered at a dosage of 80 mg per day.

21. (Withdrawn) A method of treating a subject with gynecomastia, said method comprising the step of administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof.

22. (Withdrawn) The method according to claim 21, wherein said anti-estrogen is a selective estrogen receptor modulator (SERM).

23. (Withdrawn) The method according to claim 21, wherein said anti-estrogen is a triphenylethylene.

24. (Withdrawn) The method according to claim 21, wherein said anti-estrogen is Toremifene.

25. (Withdrawn) The method according to claim 21, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical composition in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical composition; orally administering to said subject said pharmaceutical

composition in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical composition.

26. (Withdrawn) The method according to claim 25 wherein said pharmaceutical composition is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.

27. (Withdrawn) The method according to claim 21, wherein said antiestrogen is administered at a dosage of about 20 mg per day.

28. (Withdrawn) The method according to claim 21, wherein said antiestrogen is administered at a dosage of about 40 mg per day.

29. (Withdrawn) The method according to claim 21, wherein said antiestrogen is administered at a dosage of about 60 mg per day.

30. (Withdrawn) The method according to claim 21, wherein said antiestrogen is administered at a dosage of 80 mg per day.

31. (Withdrawn) A method of suppressing, inhibiting or reducing the risk of gynecomastia, said method comprising the step of administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof.

32. (Withdrawn) The method according to claim 31, wherein the anti-estrogen is a selective estrogen receptor modulator (SERM).

33. (Withdrawn) The method according to claim 31, wherein the anti-estrogen is a triphenylethylene.

34. (Withdrawn) The method according to claim 31, wherein the anti-estrogen is

Toremifene.

35. (Withdrawn) The method according to claim 31, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical composition in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical composition; orally administering to said subject said pharmaceutical composition in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical composition.

36. (Withdrawn) The method according to claim 35, wherein said pharmaceutical composition is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.

37. (Withdrawn) The method according to claim 31, wherein said antiestrogen is administered at a dosage of about 20 mg per day.

38. (Withdrawn) The method according to claim 31, wherein said antiestrogen is administered at a dosage of about 40 mg per day.

39. (Withdrawn) The method according to claim 31, wherein said antiestrogen is administered at a dosage of about 60 mg per day.

40. (Withdrawn) The method according to claim 31, wherein said antiestrogen is administered at a dosage of 80 mg per day.